RT Journal Article
SR Electronic
T1 Screening of the H69 and V70 deletions in the SARS-CoV-2 spike protein with a RT-PCR diagnosis assay reveals low prevalence in Lyon, France
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.11.10.20228528
DO 10.1101/2020.11.10.20228528
A1 Antonin Bal
A1 Gregory Destras
A1 Alexandre Gaymard
A1 Hadrien Regue
A1 Quentin Semanas
A1 Constance d’Aubarde
A1 Geneviève Billaud
A1 Frédéric Laurent
A1 Claudia Gonzales
A1 Martine Valette
A1 Bruno Lina
A1 Florence Morfin
A1 Laurence Josset
A1 the COVID-Diagnosis HCL Study Group
YR 2020
UL http://medrxiv.org/content/early/2020/11/13/2020.11.10.20228528.abstract
AB The H69 and V70 deletions in SARS-CoV-2 spike protein have been detected in mink and human infections. We found that these deletions resulted in a false negative result for the spike target of a commercial RT-PCR assay. From August 3rd to November 1st, 39/6964 (0.56%) of positive tests performed in Lyon, France, displayed a S negative profile suggesting a limited circulation of the deleted variant. This RT-PCR assay could be useful to address the risk of the mink variant’s spreading.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialSamples used in this study were collected as part of an approved ongoing surveillance conducted by the national reference centre for respiratory viruses in Lyon, France (WHO reference laboratory providing confirmatory testing for COVID-19). The investigations were carried out in accordance with the General Data Protection Regulation (Regulation (EU) 2016/679 and Directive 95/46/EC) and the French data protection law (Law 78 17 on 06/01/1978 and Decret 2019 536 on 29/05/2019). Samples were collected for regular clinical management during hospital stay, with no additional samples for the purpose of this study. Patients were informed of the research and their non-objection approval was confirmed. This study was presented by the ethics committee of the Hospices Civils de Lyon (HCL), Lyon, France and registered on the HCL database of RIPHN studies (AGORA N 41).Funding StatementNoneAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics statement Samples used in this study were collected as part of an approved ongoing surveillance conducted by the national reference centre for respiratory viruses in Lyon, France (WHO reference laboratory providing confirmatory testing for COVID-19). The investigations were carried out in accordance with the General Data Protection Regulation (Regulation (EU) 2016/679 and Directive 95/46/EC) and the French data protection law (Law 78 17 on 06/01/1978 and Decret 2019 536 on 29/05/2019). Samples were collected for regular clinical management during hospital stay, with no additional samples for the purpose of this study. Patients were informed of the research and their non-objection approval was confirmed. This study was approved by the ethics committee of the Hospices Civils de Lyon (HCL), Lyon, France and registered on the HCL database of RIPHN studies (AGORA N 41). All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSARS-CoV-2 genomes sequenced in this study were deposited in the GISAID database (EPI_ISL_582110, EPI_ISL_582111, EPI_ISL_582112, EPI_ISL_582113, EPI_ISL_582114, EPI_ISL_582115, EPI_ISL_582116, EPI_ISL_582117, EPI_ISL_582118, EPI_ISL_582119, EPI_ISL_582120, EPI_ISL_582508, EPI_ISL_623098, EPI_ISL_623099, EPI_ISL_623100, EPI_ISL_623101, EPI_ISL_623102)